Samantha Truex has joined Atlas Venture as a venture partner. She is a former vice president of corporate development at Biogen.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Atlas Venture, a leading early stage venture capital firm, announced today that Samantha (Sam) Truex is joining the firm as a venture partner. Sam will work with the Atlas team to start and build new biotech companies aimed at bringing therapeutic innovations to patients.
Atlas Venture announces Sam Truex has joined as a Venture Partner to start and build new biotech companies aimed at bringing therapeutic innovations to patients.
Truex has held multiple executive leadership roles at Atlas portfolio companies. In 2014 she joined Atlas-founded Padlock Therapeutics as chief business officer and helped lead its acquisition by BMS for up to $600 million in 2016. She subsequently served as chief operating officer at Synlogic. Most recently, Truex was chief executive officer of Atlas-founded Quench Bio. Truex also serves as an independent board member at HotSpot Therapeutics and has consulted to Disc Medicine, Ikena Oncology, Kymera Therapeutics, and Obsidian Therapeutics. Previously, Sam served as vice president of corporate development at Biogen and in various roles at Genzyme, Chiron, and Health Advances earlier in her career. Truex is active in developing future biotech leadership talent through her creation of the Teton Biotech Mini-Internship, and through her roles as chair of the board of Thayer School of Engineering at Dartmouth and board member of Life Science Cares.
“Sam brings broad experience in building and leading biotech companies and a passion for innovative approaches to developing therapeutics,” said Bruce Booth, partner at Atlas Venture, who worked with Truex as co-founder of both Padlock Therapeutics and Quench Bio. “We are excited to welcome Sam onto our team and know she will have a tremendous impact on the next generation of Atlas companies.”
About Atlas Venture
Atlas Venture is a leading biotech venture capital firm. With the goal of doing well by doing good, we have been building breakthrough biotech startups for over 25 years. We work side by side with exceptional scientists and entrepreneurs to translate high impact science into medicines for patients. Our seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value. For more information, please visit www.atlasventure.com.